Research database
SVF Research Library
Search 52,792 real PubMed studies on SVF and adipose-derived stem cells — 53 matching records.
53 results — page 1 of 3
- Level AMeta-analysisEurope PMC
Therapeutic potential of mesenchymal stromal cells in COVID-19: a meta-analysis of clinical trials conducted since the pandemic onset
Meta-analysis with a reported sample of 1080 on Chronic Inflammation, published in Stem Cell Res Ther (2026) — summary generated from the PubMed abstract.
- 2026
- n = 1080
Stem Cell Res Ther - Level DNarrative ReviewPubMed
Mesenchymal stromal cells (MSCs) as a therapeutic agent of inflammatory disease and infectious COVID-19 virus: live or dead mesenchymal?
Narrative Review with a reported sample of 19 on Chronic Inflammation, Autoimmune Research, published in Mol Biol Rep (2024) — summary generated from the PubMed abstract.
- 2024
- n = 19
Mol Biol Rep - Level BClinical TrialEurope PMC
Mesenchymal stem cells and their derived exosomes for the treatment of COVID-19
Clinical Trial on Immune Modulation, published in World J Stem Cells (2024) — summary generated from the PubMed abstract.
- 2024
World J Stem Cells3 citations - Level CProspective StudyPubMed
Immunomodulation of adipose-derived mesenchymal stem cells on peripheral blood mononuclear cells in colorectal cancer patients with COVID-19.
Prospective Study on Immune Modulation, published in World J Gastrointest Oncol (2024) — summary generated from the PubMed abstract.
- 2024
World J Gastrointest Oncol5 citations - Level DLaboratory StudyPubMed
Targeting Cytokines: Evaluating the Potential of Mesenchymal Stem Cell Derived Extracellular Vesicles in the Management of COVID-19.
Laboratory Study on Chronic Inflammation, Immune Modulation, published in Stem Cell Rev Rep (2024) — summary generated from the PubMed abstract.
- 2024
Stem Cell Rev Rep - Level DNarrative ReviewEurope PMC
Critical roles of cytokine storm and bacterial infection in patients with COVID-19: therapeutic potential of mesenchymal stem cells
Narrative Review with a reported sample of 19, published in Inflammopharmacology (2023) — summary generated from the PubMed abstract.
- 2023
- n = 19
Inflammopharmacology9 citations - Level ASystematic ReviewEurope PMC
Effectiveness of RCTs Pooling Evidence on Mesenchymal Stem Cell (MSC) Therapeutic Applications During COVID-19 Epidemic: A Systematic Review
Systematic Review with a reported sample of 574, published in Biologics (2023) — summary generated from the PubMed abstract.
- 2023
- n = 574
Biologics5 citations - Level BClinical TrialEurope PMC
Mechanisms of Potential Therapeutic Utilization of Mesenchymal Stem Cells in COVID-19 Treatment
Clinical Trial on Immune Modulation, published in Cell Transplant (2023) — summary generated from the PubMed abstract.
- 2023
Cell Transplant9 citations - Level BClinical TrialPubMed
Mesenchymal stem cells in lung diseases and their potential use in COVID-19 ARDS: A systematized review.
Clinical Trial on Immune Modulation, published in Clinics (Sao Paulo) (2023) — summary generated from the PubMed abstract.
- 2023
Clinics (Sao Paulo)1 citations - Level CProspective StudyPubMed
Exosomes from Adipose Tissue-derived Mesenchymal Stem Cells Induce Regulatory T Cells in COVID-19 Patients.
Prospective Study with a reported sample of 20 on Chronic Inflammation, Immune Modulation, published in Iran J Allergy Asthma Immunol (2023) — summary generated from the PubMed abstract.
- 2023
- n = 20
Iran J Allergy Asthma Immunol - Level AMeta-analysisEurope PMC
Safety and efficacy of mesenchymal stem cells in COVID-19 patients: A systematic review and meta-analysis
Meta-analysis with a reported sample of 19, published in Immun Inflamm Dis (2023) — summary generated from the PubMed abstract.
- 2023
- n = 19
Immun Inflamm Dis4 citations - Level CProspective StudyPubMed
Adipose-derived, autologous mesenchymal stem cell therapy for patients with post-COVID-19 syndrome: an intermediate-size expanded access program.
Prospective Study on Systemic / IV, published in Stem Cell Res Ther (2023) — summary generated from the PubMed abstract.
- 2023
Stem Cell Res Ther6 citations - Level BRandomized Controlled TrialPubMed
Safety of multiple intravenous infusions of adipose-derived mesenchymal stem cells for hospitalized cases of COVID-19: a randomized controlled trial.
Randomized Controlled Trial with a reported sample of 48 on Systemic / IV, published in Front Med (Lausanne) (2023) — summary generated from the PubMed abstract.
- 2023
- n = 48
Front Med (Lausanne)4 citations - Level BClinical TrialEurope PMC
Potency of Mesenchymal Stem Cell and Its Secretome in Treating COVID-19
Clinical Trial with a reported sample of 19, published in Regen Eng Transl Med (2022) — summary generated from the PubMed abstract.
- 2022
- n = 19
Regen Eng Transl Med23 citations - Level BClinical TrialEurope PMC
Mesenchymal stem cells and their derived exosomes to combat Covid-19
Clinical Trial, published in Rev Med Virol (2022) — summary generated from the PubMed abstract.
- 2022
Rev Med Virol43 citations - Level BClinical TrialEurope PMC
Clinical efficacy and mechanism of mesenchymal stromal cells in treatment of COVID-19
Clinical Trial on Immune Modulation, published in Stem Cell Res Ther (2022) — summary generated from the PubMed abstract.
- 2022
Stem Cell Res Ther10 citations - Level BClinical TrialPubMed
Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications.
Clinical Trial with a reported sample of 19 on Chronic Inflammation, published in Cell Mol Life Sci (2022) — summary generated from the PubMed abstract.
- 2022
- n = 19
Cell Mol Life Sci32 citations - Level DNarrative ReviewEurope PMC
Regenerative therapy by using mesenchymal stem cells-derived exosomes in COVID-19 treatment. The potential role and underlying mechanisms
Narrative Review on Chronic Inflammation, Immune Modulation, published in Regen Ther (2022) — summary generated from the PubMed abstract.
- 2022
Regen Ther8 citations - Level BClinical TrialPubMed
Nebulized exosomes derived from allogenic adipose tissue mesenchymal stromal cells in patients with severe COVID-19: a pilot study.
Clinical Trial with a reported sample of 7, published in Stem Cell Res Ther (2022) — summary generated from the PubMed abstract.
- 2022
- n = 7
Stem Cell Res Ther135 citations - Level ASystematic ReviewEurope PMC
Association between Mesenchymal Stem Cells and COVID-19 Therapy: Systematic Review and Current Trends
Systematic Review with a reported sample of 19, published in Biomed Res Int (2022) — summary generated from the PubMed abstract.
- 2022
- n = 19
Biomed Res Int5 citations - Level BClinical TrialEurope PMC
Immunomodulation of Mesenchymal Stem Cells in Acute Lung Injury: From Preclinical Animal Models to Treatment of Severe COVID-19
Clinical Trial on Immune Modulation, published in Int J Mol Sci (2022) — summary generated from the PubMed abstract.
- 2022
Int J Mol Sci19 citations - Level DNarrative ReviewPubMed
Hair Loss and Telogen Effluvium Related to COVID-19: The Potential Implication of Adipose-Derived Mesenchymal Stem Cells and Platelet-Rich Plasma as Regenerative Strategies.
Narrative Review with a reported sample of 19 on Hair Loss, published in Int J Mol Sci (2022) — summary generated from the PubMed abstract.
- 2022
- n = 19
Int J Mol Sci21 citations - Level AMeta-analysisEurope PMC
Efficacy of umbilical cord mesenchymal stromal cells for COVID-19: A systematic review and meta-analysis
Meta-analysis with a reported sample of 293 on Chronic Inflammation, Immune Modulation, published in Front Immunol (2022) — summary generated from the PubMed abstract.
- 2022
- n = 293
Front Immunol5 citations - Level ASystematic ReviewEurope PMC
Clinical efficacy analysis of mesenchymal stem cell therapy in patients with COVID-19: A systematic review
Systematic Review with a reported sample of 19, published in World J Clin Cases (2022) — summary generated from the PubMed abstract.
- 2022
- n = 19
World J Clin Cases4 citations
In-depth reviewed studies (full Thai translation)
Evidence system- Level ARandomized Controlled Trial
Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial
A multicentre randomized trial in 480 knee osteoarthritis patients comparing SVF, BMAC and umbilical cord MSCs against corticosteroid injection. At 12 months no cell product outperformed the steroid control.
- 2023
- United States
- n = 480
- Level AMeta-analysis
Intra-articular Injection of Autologous Adipose-Derived Stem Cells or Stromal Vascular Fractions: Are They Effective for Patients With Knee Osteoarthritis? A Systematic Review With Meta-analysis of Randomized Controlled Trials
Pooled five RCTs comparing ADSC/SVF injection with placebo or hyaluronic acid, finding significant pain and function improvement at 6 and 12 months.
- 2023
- South Korea
- Level AMeta-analysis
Rapid-acting pain relief in knee osteoarthritis: autologous-cultured adipose-derived mesenchymal stem cells outperform stromal vascular fraction: a systematic review and meta-analysis
Analysed 31 studies with 1,406 patients: cultured ADMSCs reduced pain from month 3, whereas SVF reached significance only at 12 months.
- 2024
- South Korea
- n = 1406